drugset
drugset / Trial / NCT05053737

Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC

NCT05053737 ↗

Phase 1 Completed 11 enrolled University of Colorado, Denver Genentech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the outcomes of patients with specific head and neck cancer after undergoing radiation therapy with atezolizumab followed by surgery then radiation with or without chemotherapy according to national guidelines.

Timeline

Start
2021-11-02
Primary completion
2023-11-24
Completion
2024-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous

Indications

head and neck squamous cell carcinoma